Document is current
Any future updates will be listed below
-
Authors
Ghisai, Santoesha A. https://orcid.org/0000-0002-3289-4294
van Hijfte, Levi
Vallentgoed, Wies R.
Tesileanu, C. Mircea S.
de Heer, Iris
Kros, Johan M.
Sanson, Marc
Gorlia, Thierry
Wick, Wolfgang
Vogelbaum, Michael A.
Brandes, Alba A.
Franceschi, Enrico
Clement, Paul M.
Nowak, Anna K.
Golfinopoulos, Vassilis
van den Bent, Martin J.
French, Pim J.
Hoogstrate, Youri
-
Funding
Funding for this research was provided by:
MSD Sharp and Dohme
Vereniging Heino
Stichting STOPhersentumoren
Brain Tumour Charity (GN-000577)
KWF Kankerbestrijding (10685)
NRG Oncology (U10CA180868, U10CA180822)
Cancer Research UK (CRUK/07/028)
Cancer Australia (1026842, 1078655)
- License Information
-
More Information
Article History
Received: 6 June 2024
Revised: 17 September 2024
Accepted: 30 September 2024
First Online: 9 October 2024
Declarations
:
: P.M. Clement reports other support from EORTC during the conduct of the study; fees (to institution) from Bayer, Merck, Leo Pharma, Rakuten Medical, Takeda, and Bristol Myers Squibb (BMS); fees and nonfinancial support from MSD; and grants from AstraZeneca outside the submitted work; also fees for occasional advice to government agencies such as FAGG/EMA, as well as being a member of CTG (substitute) in Belgium. M.J. van den Bent reports consulting for Boehringer Ingelheim, F. Hoffman-La Roche, Fore Biotherapeutics, Genenta, Incyte Corporation, AnHeart therapeutics, Mundipharma, SymBio Pharma and Servier Affaires Medicales.
: Written informed consent was obtained from all participants in accordance with institutional and national ethical guidelines.
